Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

97.13 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 97.13
Bid (Size) 95.25 (1)
Ask (Size) 101.30 (1)
Prev. Close 97.13
Today's Range 97.13 - 97.13
52wk Range 92.19 - 108.78
Shares Outstanding N/A
Dividend Yield 3.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds... 
Via Benzinga
Exposures Product Safety
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
The company is projected to bring in increasing sales through at least 2029. 
Via Investor's Business Daily

Performance

YTD
-3.83%
-3.83%
1 Month
+1.31%
+1.31%
3 Month
-9.86%
-9.86%
6 Month
+3.79%
+3.79%
1 Year
-5.28%
-5.28%

More News

Read More
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
Via Talk Markets
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
Via Investor's Business Daily
Looking At Novartis's Recent Unusual Options Activity
Via Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Why Novartis Stock Topped the Market on Tuesday
Via The Motley Fool
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Via Benzinga
Exposures Product Safety
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Via Benzinga
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
Via Benzinga
Topics Bonds
Exposures Debt Markets
Top Analyst Reports For Novartis, American Express & ConocoPhillips
Via Talk Markets
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
Via Investor's Business Daily
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Via Benzinga
Exposures Product Safety
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Via Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Via The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Via The Motley Fool
Topics ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Via Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.